A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept

CompletedOBSERVATIONAL

Enrollment

250

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Luspatercept

According to product label

Trial Locations (1)

RTI Health Solutions, Research Triangle Park